Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Revenue (2019 - 2025)

Historic Revenue for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $2.8 million.

  • Kymera Therapeutics' Revenue fell 2611.6% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238000.0, marking a year-over-year decrease of 10027.18%. This contributed to the annual value of $3.1 million for FY2024, which is 9605.56% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Revenue is $2.8 million, which was down 2611.6% from $11.5 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Revenue high stood at $47.9 million for Q4 2023, and its period low was -$36.6 million during Q4 2024.
  • Moreover, its 5-year median value for Revenue was $11.5 million (2022), whereas its average is $12.5 million.
  • Per our database at Business Quant, Kymera Therapeutics' Revenue skyrocketed by 46322.99% in 2021 and then crashed by 17638.72% in 2024.
  • Kymera Therapeutics' Revenue (Quarter) stood at $15.3 million in 2021, then rose by 5.66% to $16.1 million in 2022, then soared by 196.7% to $47.9 million in 2023, then tumbled by 176.39% to -$36.6 million in 2024, then soared by 107.56% to $2.8 million in 2025.
  • Its Revenue was $2.8 million in Q3 2025, compared to $11.5 million in Q2 2025 and $22.1 million in Q1 2025.